Vaccitech plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William J. Enright MBA
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The SchrOedinger Building Oxford United Kingdom OX4 4GE
- IPO Date
- Apr 30, 2021
- CIK
- 0001828185
- Website
- vaccitech.co.uk
- Similar Companies
- Business
- Barinthus Biotherapeutics plc, formerly known as Vaccitech plc, is a clinical-stage biopharmaceutical company advancing novel T cell immunotherapeutic candidates across chronic infectious diseases, oncology, and autoimmune conditions. The company's therapeutic development pipeline features VTP-300, currently undergoing Phase 2b clinical trials as a potential functional cure for chronic hepatitis B infection, with interim efficacy data released in late 2023. VTP-200 is in Phase 1b/2 studies, evaluating a non-invasive approach for persistent high-risk human papillomavirus (HPV) infection, with the full dataset anticipated in the second quarter of 2024. For prostate cancer, the firm's VTP-850 candidate recently initiated dosing in a Phase 1/2 clinical trial in June 2023. Additionally, VTP-600, an immunotherapeutic for non-small cell lung cancer, is in Phase 1/2a clinical development through a partnership with Cancer Research UK. The company has also expanded into autoimmune indications with VTP-1000, its lead SNAPvax technology candidate for celiac disease, for which an Investigational New Drug application was expected in the latter half of 2023. Barinthus Biotherapeutics utilizes a proprietary T cell-inducing platform incorporating modified simian adenoviral and Modified Vaccinia Ankara (MVA) boost vectors, along with the acquired SNAPvax technology. The company also generates revenue through its share of milestones and royalties from Vaxzevria, the COVID-19 vaccine co-invented with the University of Oxford and licensed globally to AstraZeneca. Originally established as Vaccitech in 2016, the company changed its name to Barinthus Biotherapeutics in November 2023 and maintains its headquarters in Oxford, United Kingdom.
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Vaccitech to Present at Upcoming October Investor & Scientific Conferences
Vaccitech to Present at Upcoming September Investors Conferences
Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why
Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens
Vaccitech to Present at the Jefferies Healthcare Conference
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
Wall Street Analysts Believe Vaccitech PLC Sponsored ADR (VACC) Could Rally 113%: Here's is How to Trade
Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial
Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development
Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
Vaccitech: The Next Big Vaccine Trade
Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments